Currently out of the existing stock ratings of Matthew Caufield, 112 are a BUY (84.85%), 20 are a HOLD (15.15%).

Matthew Caufield

Work Performance Price Targets & Ratings Chart

Analyst Matthew Caufield, carries an average stock price target met ratio of 27.02% that have a potential upside of 25.65% achieved within 63 days. Previously, Matthew Caufield worked at HC WAINWRIGHT.

Matthew Caufield’s has documented 246 price targets and ratings displayed on 21 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on AKBA, Akebia Ther at 06-Feb-2026.

Wall Street Analyst Matthew Caufield

Analyst best performing recommendations are on HLVX (HILLEVAX).
The best stock recommendation documented was for MLYS (MINERALYS THERAPEUTICS, COMMON STOCK) at 8/13/2025. The price target of $42 was fulfilled within 58 days with a profit of $28.44 (209.73%) receiving and performance score of 36.16.

Average potential price target upside

of $19.11 (151.3%) on MLYS (MINERALYS THERAPEUTICS, COMMON STOCK).
of $12.26 (44.36%) on LENZ (LENZ THERAPEUTICS).
of $11.6 (68.02%) on ISEE (IVERIC BIO).

ALDX Aldeyra The EYEN Eyenovia FDMT 4D Molecular Therapeutics ISEE IVERIC bio OCUP Ocuphire Pharma OPT Opthea Ltd LYRA Lyra Therapeutics UBX Unity Biotechnology GMTX Gemini Therapeutics ADVM Adverum Biotechnologies DMAC DiaMedica Therapeutics KOD Kodiak Sciences OPTN OptiNose PHAT Phathom Pharmaceuticals HLVX Hillevax LENZ LENZ Therapeutics MLYS Mineralys Therapeutics, Common Stock FBLG FibroBiologics, Common Stock SRZN Surrozen IMUX Immunic AKBA Akebia Ther

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Thomas Shrader (BTIG)